Skip to main content

The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.

Fallopian tube cancer statistics

Explore statistics on gynaecological cancer, including the number of new cases, deaths, survival rates, and overall prevalence.

6,576 Estimated number of new cases of gynaecological cancer diagnosed in 2021
9.3% Estimated % of all new female cancer cases diagnosed in 2021
2,139 Estimated number of deaths from gynaecological cancer in 2021
9.9% Estimated % of all female deaths from cancer in 2021
71% Chance of surviving at least 5 years (2013–2017)
21,087 Females living with gynaecological cancer at the end of 2016 (diagnosed in the 5 year period 2012 to 2016)

The following material has been sourced from the Australian Institute of Health and Welfare

Gynaecological cancer incorporates ICD-10 cancer codes C51 (Malignant neoplasm of vulva), C52 (Malignant neoplasm of vagina), C53 (Malignant neoplasm of cervix), C54 (Malignant neoplasm of corpus uteri), C55 (Malignant neoplasm of uterus, part unspecified), C56 (Malignant neoplasm of ovary), C57 (Malignant neoplasm of other and unspecified female genital organs) and C58 (Malignant neoplasm of placenta).

New cases

In 2017, gynaecological cancer as a group represents 9.3% of cancers diagnosed in women and the most common gynaecological cancer was uterine cancer (see details on the uterine cancer page).

In 2017, there were 5,823 new cases of gynaecological cancers diagnosed in Australia. In 2021, it is estimated that 6,576 new cases of gynaecological cancers will be diagnosed in Australia. In 2021, it is estimated that a female has a 1 in 23 (or 4.4%) risk of being diagnosed with a gynaecological cancer by the age of 85.

Figure 1. Estimated most common cancers diagnosed among females, 2021
Figure 1. Estimated most common cancers diagnosed among females, 2021

Notes 

In 2017, the age-standardised incidence rate was 41 cases per 100,000 females. In 2021, it is estimated that the age-standardised incidence rate will be 42 cases per 100,000 females. The incidence rate for gynaecological cancers is expected to increase with age, peaking at age group 75–79 years.

Figure 2. Age-standardised incidence rates for gynaecological cancers, 1982 to 2017
Figure 2. Age-standardised incidence rates for gynaecological cancers, 1982 to 2017

Notes: Data sourced from AIHW Cancer Data in Australia 2021 web report and supplementary data tables 

The number of new cases of gynaecological cancers diagnosed increased from 2,951 in 1982 to 5,823 in 2017. Over the same period, the age-standardised incidence rate decreased from 44 cases per 100,000 females in 1982 to 41 cases per 100,000 females in 2017.

Deaths 

In 2019, gynaecological cancer as a group represents 10% of cancer related deaths in women and ovarian cancer was the most common cause of gynaecological cancer-related death. 

In 2019, there were 2,150 deaths from gynaecological cancers in Australia. In 2021, it is estimated that there will be 2,139 deaths. In 2021, it is estimated that a female has a 1 in 71 (or 1.4%) risk of dying from a gynaecological cancer by the age of 85.

Figure 3. Estimated most common causes of cancer death among females, 2021
Figure 3. Estimated most common causes of cancer death among females, 2021

Notes 

In 2019, the age-standardised mortality rate was 13 deaths per 100,000 females. In 2021, it is estimated that the age-standardised mortality rate will remain 13 deaths per 100.000 females). The mortality rate for gynaecological cancer is expected to increase with age.

Figure 4. Age-standardised mortality rates for gynaecological cancers, 1982 to 2019
Figure 4. Age-standardised mortality rates for gynaecological cancers, 1982 to 2019

Note: Data sourced from AIHW Cancer Data in Australia 2021 web report and supplementary data tables

The number of deaths from gynaecological cancers increased from 1,235 in 1982 to 2,150 in 2019. Over the same period, the age-standardised mortality rate decreased from 19 deaths per 100,000 females in 1982 to 13 deaths per 100,000 in 2019. 

Survival 

In 2013–2017, females diagnosed with gynaecological cancers had a 71% chance of surviving for at least five years compared to their counterparts in the general Australian population. Between 1988–1992 and 2013–2017, five-year relative survival for gynaecological cancers improved from 63% to 71%.

Figure 5. 5-year relative survival for gynaecological cancers, 1988–1992 to 2013–2017
Figure 5. 5-year relative survival for gynaecological cancers, 1988–1992 to 2013–2017

Notes: Data sourced from AIHW Cancer Data in Australia 2021 web report and supplementary data tables

Prevalence 

At the end of 2016, there were 5,283 females living who had been diagnosed with gynaecological cancers that year, 21,087 females living who had been diagnosed with gynaecological cancers in the previous 5 years (from 2012 to 2016) and 65,764 females living who had been diagnosed with gynaecological cancers in the previous 35 years (from 1982 to 2016).

For more information on cancer data, see the NCCI website  

The National Cancer Control Indicators (NCCI) are a set of indicators across the continuum of cancer care, from Prevention and Screening through to Diagnosis, Treatment, Psychosocial care, Research and Outcomes.  The NCCI website allows users to see visual representations of data on each indicator through interactive charts. 

Cancer Australia

Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.

If you would like an interpreter to help you understand any information on this website, please call TIS National on 131 450 and ask them to call Cancer Australia on 02 9357 9400. Our business hours are 9am to 5pm, Monday to Friday.

© 2025 Cancer Australia. All rights reserved.